프리시젼바이오

335810· KOSDAQ· Health Care· Health Care Equipment & Services

₩1,310+5.56%

2026-08-04

Financials

Valuation Metrics

프리시젼바이오's Market Cap is ₩288B. At end of 2025 it was ₩583B. Ranked #2092 of 2,436 in KR market (top 86%), #1336 of 1,649 on KOSDAQ (top 81%), #86 of 96 in Health Care Equipment & Services (top 90%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	28.75B KRW	KR#2,092/2,436 Sec#86/96
Revenue	22.34B KRW	KR#2,112/2,436 Sec#71/96
Net Income	-7.87B KRW	KR—/2,436 Sec—/96
Total Assets	63.38B KRW	KR#2,053/2,436 Sec#67/96
Net Assets	43.20B KRW	KR#1,971/2,436 Sec#67/96
Employees	96	KR#1,657/2,436 Sec#62/96
Value
P/B	0.67x	KR#1,100/2,436 Sec#21/96
P/S	1.29x	KR#1,568/2,436 Sec#40/96
FCF Yield	-5.81%	KR—/2,436 Sec—/96
Profitability
ROE	-18.23%	KR#2,038/2,436 Sec#71/96
ROA	-12.42%	KR#2,130/2,436 Sec#73/96
Op. Margin	-17.28%	KR#2,090/2,436 Sec#70/96
Revenue Growth	52.18%	KR#285/2,436 Sec#9/96
Financial Health
Debt Ratio	146.72%	KR#1,145/2,436 Sec#57/96
Total Debt	13.11B KRW	KR#1,524/2,436 Sec#47/96
FCF	-1.67B KRW	KR#1,319/2,436 Sec#40/96
Cash	4.28B KRW	KR#2,055/2,436 Sec#73/96
Current Ratio	1.47x	KR#1,332/2,436 Sec#69/96
Performance
1Y Return	-55.44%	KR#2,172/2,436 Sec#79/96
1M Return	-12.08%	KR#1,879/2,436 Sec#73/96
From 52W High	-62.62%	KR#1,842/2,436 Sec#66/96
1Y MDD	-64.16%	KR#1,654/2,436 Sec#56/96
Trading
Volume	18,307 shares	KR#1,891/2,436 Sec#77/96
Foreign Own.	0.21%	KR—/2,436 Sec—/96
Per Share
EPS	-531 KRW	KR—/2,436 Sec—/96
BPS	1,968 KRW	KR#2,037/2,436 Sec#68/96

Company Info

CEO 김한신

Employees 96

Founded 2009

HQ 대전시 유성구, KR

Website precision-bio.com/

동사는 2009년 테라웨이브㈜ 설립으로 첨단 광학분석기기 제작 기술을 발전시키고, 2015년 나노디텍을 자회사로 편입해 글로벌 체외진단 업체로의 도약 기반을 마련함. 인공위성 카메라 이미징 기술을 활용해 심근경색, 감염성 질환 등의 진단제품을 생산하며, 2021년부터 임상화학진단 제품을 본격 생산하여 검사기와 카트리지를 판매함. 디지털 헬스케어 플랫폼 개발을 통해 기존 현장진단 제품과 결합해 시너지를 창출하고 있음. 프리시젼바이오는 2009년에 설립되었으며 대전시 유성구에 본사를 두고 있습니다.